Associated Papers
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
Saturation profiling of drug-resistant genetic variants using prime editing.
Kim Y et al.
Nature Biotechnology, 2025
Comprehensive molecular profiling of advanced NSCLC using NGS: Prevalence of druggable mutations and clinical trial opportunities in the ATLAS study.
Serna-Blasco R et al.
Lung Cancer (amsterdam, Netherlands), 2025
Circulating tumor DNA profiling for non-invasive genomic analysis in Indian lung cancer patients: A real-world experience.
Jha P et al.
The Journal of Liquid Biopsy, 2025
Discovery and preclinical evaluations of drug candidate DA-0157 capable of overcoming EGFR drug-resistant mutation C797S and EGFR/ALK co-mutations.
He P et al.
European Journal of Medicinal Chemistry, 2025
Predicting Resistance to Small Molecule Kinase Inhibitors.
Nagarajan A et al.
Journal of Chemical Information and Modeling, 2025
A rare epidermal growth factor receptor T790M/cis-C797S/L718Q compound mutation in a lung adenocarcinoma patient who did not derive any benefit from combination therapy with afatinib and bevacizumab.
Meng X et al.
Sage Open Medical Case Reports, 2025
Osimertinib-induced DNA resistance mutations in cerebrospinal fluid of epidermal growth factor receptor-mutated non-small-cell lung carcinoma patients developing leptomeningeal metastases: Osimertinib Resistance Analysis-leptomeningeal metastases study.
van der Wel JWT et al.
Neuro-oncology, 2024
ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial.
Soo RA et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2024
Clinical Utility of Circulating Tumor DNA for Detecting Lung Cancer Mutations by Targeted Next-Generation Sequencing With Insufficient Tumor Samples.
Sun Y et al.
Journal of Clinical Laboratory Analysis, 2024
Beyond tobacco: genomic disparities in lung cancer between smokers and never-smokers.
Garrido J et al.
Bmc Cancer, 2024
Follicular cell-derived thyroid carcinomas harboring novel genetic BRAFNON-V600E mutations: real-world data obtained using a multigene panel.
von Ammon JL et al.
Archives of Endocrinology and Metabolism, 2024
Case report: MSI-H, EGFR mutation, and ground-glass nodules as diffuse pulmonary hematogenous metastases.
He L et al.
Frontiers in Immunology, 2024
Biomarker testing in lung cancer: from bench to bedside.
Batra U et al.
Oncology Reviews, 2024
The treatment of patients with non-small cell lung cancer carrying uncommon EGFR mutations, HER2 mutations, or brain metastases: a systematic review of pre-clinical and clinical findings for dacomitinib.
Yang LL et al.
Translational Cancer Research, 2023
Germline EGFR mutations in lung cancer (Review).
Liu M et al.
Oncology Letters, 2023
The Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer: From Molecular Mechanisms to Clinical Application of New Therapeutic Strategies.
Laface C et al.
Pharmaceutics, 2023
Structure-Guided Strategies of Targeted Therapies for Patients with EGFR-Mutant Non-Small Cell Lung Cancer.
Du Z et al.
Biomolecules, 2023
Molecular profiling of solid tumors by next-generation sequencing: an experience from a clinical laboratory.
Bhai P et al.
Frontiers in Oncology, 2023
Molecular landscape and therapeutic alterations in Asian soft-tissue sarcoma patients.
Gan M et al.
Cancer Medicine, 2022
Afatinib, an effective treatment for patient with lung squamous cell carcinoma harboring uncommon EGFR G719A and R776C co-mutations.
Han C et al.
Journal of Cancer Research and Clinical Oncology, 2022
Efficacy of dacomitinib in patients with non-small cell lung cancer carrying complex EGFR mutations: a real-world study.
Li HS et al.
Journal of Thoracic Disease, 2022
An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer.
To C et al.
Nature Cancer, 2022
Utility of the Ba/F3 cell system for exploring on-target mechanisms of resistance to targeted therapies for lung cancer.
Koga T et al.
Cancer Science, 2022
Amivantamab (JNJ-61186372) induces clinical, biochemical, molecular, and radiographic response in a treatment-refractory NSCLC patient harboring amplified triple EGFR mutations (L858R/ T790M/G796S) in cis.
Nagasaka M et al.
Lung Cancer (amsterdam, Netherlands), 2022
Pedigree analysis of the EGFR p.V1010M germline mutation in a family with a family history of non-small-cell lung cancer.
Li N et al.
Annals of Translational Medicine, 2022
Effective treatment of pulmonary adenocarcinoma harboring triple EGFR mutations of L858R, T790M, cis-G796s/cis-C797s by osimertinib, brigatinib, and bevacizumab combination therapy: A case report.
Chang Y et al.
Respiratory Medicine Case Reports, 2022
Osimertinib-Centered Therapy Against Uncommon Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer- A Mini Review.
Song C et al.
Frontiers in Oncology, 2022
Iterative Upgrading of Small Molecular Tyrosine Kinase Inhibitors for EGFR Mutation in NSCLC: Necessity and Perspective.
Zhu J et al.
Pharmaceutics, 2021
Fighting tertiary mutations in EGFR-driven lung-cancers: Current advances and future perspectives in medicinal chemistry.
Scalvini L et al.
Biochemical Pharmacology, 2021
Molecular pathogenesis of hereditary lung cancer: a literature review.
Rammal S et al.
Pharmacogenomics, 2021
High Incidence of C797S Mutation in Patients With Long Treatment History of EGFR Tyrosine Kinase Inhibitors Including Osimertinib.
Osoegawa A et al.
Jto Clinical and Research Reports, 2021
Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in Non-Small Cell Lung Cancer: A Review.
Karlsen EA et al.
Cells, 2021
Activity of tarloxotinib-E in cells with EGFR exon-20 insertion mutations and mechanisms of acquired resistance.
Nishino M et al.
Thoracic Cancer, 2021
The next tier of EGFR resistance mutations in lung cancer.
Tumbrink HL et al.
Oncogene, 2021
Case Report: Dacomitinib May Not Benefit Patients Who Develop Rare Compound Mutations After Later-Line Osimertinib Treatment.
Li HS et al.
Frontiers in Oncology, 2021
Mutant-Selective Allosteric EGFR Degraders are Effective Against a Broad Range of Drug-Resistant Mutations.
Jang J et al.
Angewandte Chemie (international Ed. in English), 2020
Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non-small cell lung cancer: Analysis of over 8000 cases.
Mack PC et al.
Cancer, 2020
The contribution of hereditary cancer-related germline mutations to lung cancer susceptibility.
Liu M et al.
Translational Lung Cancer Research, 2020
Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR Mutations.
Starrett JH et al.
Cancer Research, 2020
Impact and Diagnostic Gaps of Comprehensive Genomic Profiling in Real-World Clinical Practice.
Singh AP et al.
Cancers, 2020
Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells.
Hamid AB et al.
Cancers, 2020
Absence of EGFR C797S Mutation in Tyrosine Kinase Inhibitor-Naïve Non-Small Cell Lung Cancer Tissues.
Oscorbin IP et al.
Pathology Oncology Research : Por, 2020
Defining the landscape of ATP-competitive inhibitor resistance residues in protein kinases.
Persky NS et al.
Nature Structural & Molecular Biology, 2020
The Immunogenic Potential of Recurrent Cancer Drug Resistance Mutations: An In Silico Study.
Punta M et al.
Frontiers in Immunology, 2020